Tag : combination

Latest News

Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death Source link...
Gastroenterology

Combination of haploidentical haematopoietic stem cell transplantation with an unrelated cord-blood unit in patients with severe aplastic anemia: a report of 146 cases

Newsemia
Combination of haploidentical haematopoietic stem cell transplantation with an unrelated cord-blood unit in patients with severe aplastic anemia: a report of 146 cases Source link...
Pharma / Biotech

Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.

Newsemia
Related Articles Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide,...
Pharma / Biotech

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer.

Newsemia
Related Articles Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer. Invest New Drugs. 2020 Mar 07;:...
Gastroenterology

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study

Newsemia
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b,...
Pharma / Biotech

Pharmacokinetics and anti-inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses.

Newsemia
Related Articles Pharmacokinetics and anti-inflammatory effects of flunixin meglumine as a sole agent and in combination with phenylbutazone in exercised Thoroughbred horses. Equine Vet J....
Pharma / Biotech

Investigation of pre-clinical pharmacokinetic parameters of atovaquone nanosuspension prepared using pH based precipitation method and its pharmacodynamic properties in a novel artemisinin combination.

Newsemia
Related Articles Investigation of pre-clinical pharmacokinetic parameters of atovaquone nanosuspension prepared using pH based precipitation method and its pharmacodynamic properties in a novel artemisinin combination....
Pediatrics

Combination drug therapy for childhood brain tumors shows promise in laboratory models

Newsemia
In experiments with human cells and mice, researchers report evidence that combining the experimental cancer medication TAK228 (also called sapanisertib) with an existing anti-cancer drug...
Pharma / Biotech

Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.

Newsemia
Related Articles Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Pharmacotherapy. 2020 Feb 15;: Authors: Smith JR, Rybak JM, Claeys...
Latest News

Advanced X-ray combination technique aids tuberculosis and osteoporosis research

Newsemia
With an advanced X-ray combination technique, scientists have traced nanocarriers for tuberculosis drugs within cells with very high precision. Source link...
Latest News

Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer

Newsemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the completion of a supplemental Biologics License...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy